DDR2 Mutation Detection for Melanoma Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for melanoma and basal cell carcinoma lack specificity and sensitivity, particularly in identifying novel mutations that could serve as therapeutic targets, such as those in the DDR2 gene, which are not adequately addressed by existing genetic testing protocols.
Innovation Solution
The development of methods to analyze biological samples for specific mutations in the DDR2 gene, including R105C, P321L, R458H, S467F, P476S, I488S, F574C, S667F, R680L, L701F, R742Q, and T836A for melanoma, and N146K, R399Q, and S702F for basal cell carcinoma, to diagnose and predict response to kinase inhibitors, utilizing sequencing techniques and DDR2 inhibitors for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for melanoma and basal cell carcinoma, then general cancer detection is possible, but specificity and sensitivity for identifying novel mutations like DDR2 are insufficient
Solution Approach 1:
The patent segments the diagnostic process into two distinct parts: (1) general cancer detection using existing methods, and (2) targeted mutation analysis specifically for DDR2 and other novel mutations. This segmentation allows the patent to maintain simplicity for general screening while adding specialized sensitivity for mutation detection without requiring complete redesign of the diagnostic workflow.
Solution Approach 2:
The patent performs preliminary identification of cancer type (melanoma or basal cell carcinoma) using existing diagnostic methods before applying the specialized mutation detection protocol. This preliminary action enables the system to activate the more sensitive and complex mutation analysis only when appropriate, rather than applying it universally, thus balancing sensitivity improvement with operational simplicity.
2Measurement precision
If existing genetic testing protocols are used, then common genetic markers can be detected, but novel mutations in DDR2 gene cannot be adequately identified
Solution Approach 1:
The patent introduces an intermediary targeted sequencing approach that bridges the gap between standard genetic testing and comprehensive genomic analysis. This intermediary method specifically targets DDR2 and other novel mutations without requiring full genomic sequencing, thereby recovering lost mutation information while maintaining cost-effectiveness and operational feasibility.
Solution Approach 2:
The patent changes the detection parameters from standard genetic markers to specific novel mutations in DDR2 and related genes. By adjusting the detection targets and methodologies to focus on these specific parameters, the system achieves higher mutation detection accuracy while avoiding the need for exhaustive genomic analysis.
3Reliability
If targeted therapy with kinase inhibitors is implemented, then treatment efficacy can be improved for patients with specific mutations, but without accurate mutation identification, inappropriate treatment may be administered
Solution Approach 1:
The patent performs preliminary mutation identification for DDR2 and other targetable mutations before initiating kinase inhibitor therapy. This preliminary genetic characterization enables clinicians to predict treatment response with higher reliability and avoid administering targeted therapy to patients who are unlikely to benefit, thereby optimizing treatment decisions before therapy begins.
Solution Approach 2:
The patent replaces complex, difficult-to-implement mutation detection methods with a more accessible targeted sequencing approach. By substituting the detection mechanism with a streamlined protocol that focuses specifically on relevant mutations, the system makes reliable treatment prediction more easily implementable in clinical settings without requiring overly complex measurement systems.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.